Avenda Health has announced that its AI software can more accurately assess the extent of prostate cancer compared to conventional methods used by physicians. In a recent study, ten doctors evaluated 50 prostate cancer cases each, revealing that Avenda’s Unfold AI software achieved an accuracy of 84.7%. In contrast, the doctors’ accuracy ranged between 67.2% and 75.9%.
This research, conducted alongside UCLA Health and published in the Journal of Urology, indicated that AI-assisted cancer contouring significantly improved the accuracy and consistency of cancer size predictions, being 45 times more reliable than assessments made without AI.
Shyam Natarajan, assistant adjunct professor of urology at UCLA and senior author of the study, noted that the integration of AI increased both the accuracy and agreement among doctors in their evaluations.
Traditionally, physicians rely on MRI scans to determine tumor sizes. However, some tumors remain “MRI-invisible,” a challenge that AI can help overcome. Dr. Wayne Brisbane of the David Geffen School of Medicine emphasized that AI’s capabilities can surpass human limitations, offering the potential for more effective and personalized cancer treatment.
Dr. Shyam Natarajan, CEO of Avenda Health, expressed pride in the validation of their innovations through this study and recognition by the American Medical Association (AMA).
According to the American Cancer Society, approximately 1 in 8 men will be diagnosed with prostate cancer in their lifetime, with 1 in 44 succumbing to the disease. This year, there are anticipated to be 299,010 new prostate cancer cases in the U.S., leading to an estimated 35,250 deaths from the illness.